{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T07:30:59Z","timestamp":1788679859747,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ijantimicag.2020.106007","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T04:45:30Z","timestamp":1588826730000},"page":"106007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4016-1370","authenticated-orcid":false,"given":"Hartmut","family":"Derendorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106007_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106007_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101663","article-title":"Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study","author":"Gautret","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106007_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","author":"Molina","year":"2020","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.ijantimicag.2020.106007_bib0004","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.200528","article-title":"Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection","author":"Juurlink","year":"2020","journal-title":"CMAJ"},{"issue":"6","key":"10.1016\/j.ijantimicag.2020.106007_bib0005","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1128\/AAC.01723-09","article-title":"Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils","volume":"54","author":"Lemaire","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106007_bib0006","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.toxrep.2014.10.019","article-title":"Chloroquine and hydroxychloroquine binding to melanin: Some possible consequences for pathologies","volume":"1","author":"Schroeder","year":"2014","journal-title":"Toxicol Rep"},{"issue":"4","key":"10.1016\/j.ijantimicag.2020.106007_bib0007","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1124\/dmd.112.050054","article-title":"Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells)","volume":"41","author":"Kazmi","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.ijantimicag.2020.106007_bib0008","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/bod.2510090602","article-title":"The potential role of lysosomes in tissue distribution of weak bases","volume":"9","author":"MacIntyre","year":"1988","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"10.1016\/j.ijantimicag.2020.106007_bib0009","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2125.1988.tb05281.x","article-title":"A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers","volume":"26","author":"Tett","year":"1988","journal-title":"Br J Clin Pharmacol"},{"issue":"5-6","key":"10.1016\/j.ijantimicag.2020.106007_bib0010","first-page":"211","article-title":"Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture","volume":"16","author":"Carlier","year":"1994","journal-title":"Int J Tissue React"},{"issue":"1","key":"10.1016\/j.ijantimicag.2020.106007_bib0011","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1006\/excr.2002.5613","article-title":"Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages","volume":"281","author":"Tyteca","year":"2002","journal-title":"Exp Cell Res"},{"issue":"7","key":"10.1016\/j.ijantimicag.2020.106007_bib0012","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1078\/0171-9335-00180","article-title":"Azithromycin, a lysosomotropic antibiotic, impairs fluid-phase pinocytosis in cultured fibroblasts","volume":"80","author":"Tyteca","year":"2001","journal-title":"Eur J Cell Biol"},{"issue":"1-2","key":"10.1016\/j.ijantimicag.2020.106007_bib0013","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0014-2999(96)00552-3","article-title":"Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity","volume":"314","author":"Van Bambeke","year":"1996","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"10.1016\/j.ijantimicag.2020.106007_bib0014","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1128\/AAC.02904-14","article-title":"Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects","volume":"58","author":"Zheng","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.ijantimicag.2020.106007_bib0015","first-page":"481","article-title":"Gentamicin-induced lysosomal phospholipidosis in cultured rat fibroblasts. Quantitative ultrastructural and biochemical study","volume":"40","author":"Aubert-Tulkens","year":"1979","journal-title":"Lab Invest"},{"issue":"4","key":"10.1016\/j.ijantimicag.2020.106007_bib0016","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S108495210200054X","article-title":"Introduction: lysosome-related organelles","volume":"13","author":"Cutler","year":"2002","journal-title":"Semin Cell Dev Biol"},{"issue":"3","key":"10.1016\/j.ijantimicag.2020.106007_bib0017","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1083\/jcb.68.3.665","article-title":"Membrane flow during pinocytosis. A stereologic analysis","volume":"68","author":"Steinman","year":"1976","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ijantimicag.2020.106007_bib0018","unstructured":"Pfizer. Zithromax product information. 2019; Available from:https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=511."},{"issue":"5","key":"10.1016\/j.ijantimicag.2020.106007_bib0019","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ijantimicag.2010.01.023","article-title":"Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic\/pharmacodynamic indices","volume":"35","author":"Barbour","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.ijantimicag.2020.106007_bib0020","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/jps.2600770303","article-title":"role of lysosomes in hepatic accumulation of chloroquine","volume":"77","author":"MacIntyre","year":"1988","journal-title":"J Pharm Sci"},{"issue":"2 Pt 1","key":"10.1016\/j.ijantimicag.2020.106007_bib0021","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1083\/jcb.63.2.430","article-title":"Protein degradation in cultured cells. II. The uptake of chloroquine by rat fibroblasts and the inhibition of cellular protein degradation and cathepsin B1","volume":"63","author":"Wibo","year":"1974","journal-title":"J Cell Biol"},{"issue":"3","key":"10.1016\/j.ijantimicag.2020.106007_bib0022","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1083\/jcb.90.3.665","article-title":"Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages","volume":"90","author":"Poole","year":"1981","journal-title":"J Cell Biol"},{"issue":"3","key":"10.1016\/j.ijantimicag.2020.106007_bib0023","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4269\/ajtmh.2006.74.407","article-title":"Lack of a pharmacokinetic interaction between azithromycin and chloroquine","volume":"74","author":"Cook","year":"2006","journal-title":"Am J Trop Med Hyg"},{"issue":"8","key":"10.1016\/j.ijantimicag.2020.106007_bib0024","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1128\/AAC.46.8.2518-2524.2002","article-title":"Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro","volume":"46","author":"Ohrt","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.ijantimicag.2020.106007_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105932","article-title":"Chloroquine and hydroxychloroquine as available weapons to fight COVID-19","volume":"55","author":"Colson","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.ijantimicag.2020.106007_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105923","article-title":"Chloroquine for the 2019 novel coronavirus SARS-CoV-2","volume":"55","author":"Colson","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.ijantimicag.2020.106007_bib0027","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2007.05.015","article-title":"Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century","volume":"30","author":"Rolain","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106007_bib0028","doi-asserted-by":"crossref","unstructured":"Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?Int J Antimicrob Agents2020:105938.","DOI":"10.1016\/j.ijantimicag.2020.105938"},{"issue":"11","key":"10.1016\/j.ijantimicag.2020.106007_bib0029","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1128\/JVI.78.11.5642-5650.2004","article-title":"pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN","volume":"78","author":"Yang","year":"2004","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.ijantimicag.2020.106007_bib0030","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.virol.2011.02.020","article-title":"Different host cell proteases activate the SARS-coronavirus spike-protein for cell-cell and virus-cell fusion","volume":"413","author":"Simmons","year":"2011","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.ijantimicag.2020.106007_bib0031","doi-asserted-by":"crossref","first-page":"e91293","DOI":"10.1371\/journal.pone.0091293","article-title":"Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study","volume":"9","author":"Kakeya","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2020.106007_bib0032","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/649570","article-title":"Macrolide therapy in respiratory viral infections","volume":"2012","author":"Min","year":"2012","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.ijantimicag.2020.106007_bib0033","article-title":"PLAQUENIL\u00ae hydroxychloroquine sulfate tablets","year":"2015","journal-title":"Product Information"},{"issue":"5","key":"10.1016\/j.ijantimicag.2020.106007_bib0034","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4269\/ajtmh.2007.77.929","article-title":"Azithromycin\/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig","volume":"77","author":"Fossa","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2020.106007_bib0035","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106007_bib0036","series-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics","article-title":"Design and optimization of dosage regimens: pharmacokinetic data","author":"Thummel","year":"2006"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920301655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920301655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:38:05Z","timestamp":1760377085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920301655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0924857920301655"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106007","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106007"}}